The sales forecast for Modulators of the Genital System and Sex Hormones in Canada suggests a gradual decline from 2024 to 2028, with values decreasing from $15.3 to $14.6 US Dollars PPP Per Capita. The projected year-on-year variations indicate slight annual declines: -1.3% from 2024 to 2025, -1.3% from 2025 to 2026, -0.7% from 2026 to 2027, and -1.4% from 2027 to 2028. Over the five-year period, the compound annual growth rate (CAGR) reflects an average annual decrease in sales.
Future trends to watch for include:
- Impact of demographic changes, such as an aging population, on demand.
- Regulatory changes and their potential effect on market dynamics.
- Innovative treatments and therapies that could shift consumer preferences.
- Fluctuations in healthcare policies impacting affordability and accessibility.
